Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Avoid Barclays (BARC) by Christopher Ruane in The Motley Fool
- Buy easyJet (EZJ) by Tom Winnifrith in ShareProphets
- Buy easyJet (EZJ) by Steve Moore in ShareProphets
- Avoid Tekmar Group (TGP) by Steve Moore in ShareProphets
- Buy Tristel (TSTL) by Mark Rogers in The Motley Fool
- Sell Mind Gym (MIND) by Steve Moore in ShareProphets
- Neutral Rio Tinto (RIO) by UBS
- Buy Baltic Classifieds Group (BCG) by Berenberg
- Underperform Whitbread (WTB) by Bernstein
- Buy Rolls-Royce Holdings (RR.) by Bank of America
- Buy Melrose Industries (MRO) by Bank of America
- Buy BAE Systems (BA.) by Bank of America
- Buy Babcock International Group (BAB) by Bank of America
- Buy Sirius Real Estate Ltd. (SRE) by Deutsche Bank
- Buy Helical (HLCL) by Deutsche Bank
- Buy Balfour Beatty (BBY) by Deutsche Bank
- Buy Discoverie Group (DSCV) by Deutsche Bank
- Hold Derwent London (DLN) by Deutsche Bank
- Buy Workspace Group (WKP) by Deutsche Bank
- Buy AJ Bell (AJB) by Deutsche Bank
Nuformix (NFX) Share Price
Health Care Sector
NOTE: This is based on 9 open tips for Nuformix (NFX)
| Latest Bid : 0.24p | Latest Ask : 0.27p |
| High Today : 0.27p | Low Today : 0.24p |
| This Years High : 0.48p | This Years Low : 0.05p |
| Volume : 17,370,628 | MKT Cap : £3.69M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Nuformix (NFX) Overview
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. We use our expertise in discovering, developing and patenting novel drug forms with improved physical properties, to develop new products in new indications that are differentiated from the original by way of: dosage, delivery route or presentation, thus creating new and attractive commercial opportunities.Nuformix (NFX) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Canaccord Genuity | Premium Only | 2025-03-18 18:00:00 18/03/2025 | 183.33% |
| Sell | Steve Moore | Premium Only | 2023-05-25 11:25:00 25/05/2023 | -15.91% |
| Sell | Steve Moore | Premium Only | 2023-05-22 14:35:00 22/05/2023 | -15.91% |
| Sell | Steve Moore | Premium Only | 2023-05-18 14:25:00 18/05/2023 | -10.87% |
| Sell | Steve Moore | Premium Only | 2023-04-17 14:40:00 17/04/2023 | -15.91% |
Nuformix (NFX) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 0.24p | Latest Ask : 0.27p |
| High Today : 0.27p | Low Today : 0.24p |
| This Years High : 0.48p | This Years Low : 0.05p |
| Volume : 17,370,628 | MKT Cap : £3.69M |
Nuformix Overview
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. We use our expertise in discovering, developing and patenting novel drug forms with improved physical properties, to develop new products in new indications that are differentiated from the original by way of: dosage, delivery route or presentation, thus creating new and attractive commercial opportunities.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Nuformix Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Canaccord Genuity | Premium Only | 2025-03-18 18:00:00 18/03/2025 | 183.33% |
| Sell | Steve Moore | Premium Only | 2023-05-25 11:25:00 25/05/2023 | -15.91% |
| Sell | Steve Moore | Premium Only | 2023-05-22 14:35:00 22/05/2023 | -15.91% |
| Sell | Steve Moore | Premium Only | 2023-05-18 14:25:00 18/05/2023 | -10.87% |
| Sell | Steve Moore | Premium Only | 2023-04-17 14:40:00 17/04/2023 | -15.91% |